An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Phase 2
Not yet recruiting
- Conditions
- Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Avalyn Pharma Inc.
- Target Recruit Count
- 340
- Registration Number
- NCT06951217
- Locations
- 🇦🇺
Westmead Hospital, Westmead, New South Wales, Australia
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Avalyn Pharma Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06329401
- Locations
- 🇦🇷
Instituto de Medicina Respiratoria, Córdoba, Argentina
🇦🇷CIMER Centro Integral de Medicina Respiratoria, Tucumán, Argentina
🇦🇷Investigaciones En Patologias Respiratorias, Tucumán, Argentina
© Copyright 2025. All Rights Reserved by MedPath